Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy.
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year – Biotech Investments
Xlife Sciences AG / Key word(s): IPO/Market launch 16-Dec-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer